Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1099-1109

  Schultz, J D ^a   Muhlheim K ^a   Erben, P ^a   Hofheinz, R D ^a   Faber, A ^a   Thorn, C ^a   Sommer, J U ^a   Hormann K ^a   Sauter, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

HNSCC; Human papilloma virus; Imatinib; PDGF; PDGF R ; Protein tyrosine kinase; VEGF

Indexed keywords

CARBOPLATIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; WART VIRUS;

ADULT; ANGIOGENIC PROTEINS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053153632     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1403     Document Type: Article

References (73)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2002.
2. IARC (International Agency for Research on Cancer): GLOBOCAN database. Available at www-dep.iarc.fr, 2002.
3. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review: 1975-2002. National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2002/, based on November 2004 SEER data submission, posted to the SEER web site in 2005.
4. Pindborg J, Zheng KH, Kong CR, et al: Pilot survey of oral mucosa in areca (betel) nut chewers on Hainan Island of the People's Republic of China. Community Dent Oral Epidemiol 12: 195-196, 1984.
5. Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P and Lefebvre JL: Cancer of the oropharynx. Crit Rev Oncol Hematol 41: 107-122, 2002.
6. Sturgis EM and Cinciripini PM: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 110: 1429-1435, 2007.
7. Romanitan M, Näsman A, Ramqvist T, et al: Human papillomavirus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res 28: 2077-2080, 2008.
8. Chaturvedi AK, Engels EA, Anderson WF and Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619, 2008.
9. Gillison ML, D'Souza G, Westra W, et al: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100: 407-420, 2008.
10. Shiboski CH, Schmidt BL and Jordan RC: Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years. Cancer 103: 1843-1849, 2005.
11. Näsman A, Attner P, Hammarstedt L, et al: Incidence of human papilloma virus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral induced carcinoma? Int J Cancer 125: 362-366, 2009.
12. Dilianis T, Näsman A, Attner P, et al: Human papillomavirus in tonsillar cancer, an epidemic of viral carcinoma. 25th international Papillomavirus Conferenc, Malmö, Sweden, May 8-14, O17.04. 2009.
13. Hansson BG, Rosenquist K, Antonsson A, et al: Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case control study in southern Sweden. Acta Otolaryngol 125: 1337-1344, 2005.
14. Brandsma JL and Abramson AL: Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 115: 621-625, 1989.
15. Kreimer AR, Clifford GM, Boyle P and Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14: 467-475, 2005.
16. Applebaum KM, Furniss CS, Zeka A, et al: Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 99: 1801-1810, 2007.
17. Pintos J, Black MJ, Sadeghi N, et al: Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol 44: 242-250, 2008.
18. Smith EM, Ritchie JM, Summersgill KF, et al: Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 96: 449-455, 2004.
19. Koch WM, Lango M, Sewell D, Zahurak M and Sidransky D: Head and neck cancer in non-smokers: a distinct clinical and molecular entity. Laryngoscope 109: 1544-1551, 1999.
20. Tachezy R, Klozar J, Rubenstein L, et al: Demographic and risk factors in patients with head and neck tumors. J Med Virol 81: 878-887, 2009.
21. Termine N, Panzarella V, Falaschini S, et al: HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol 19: 1681-1690, 2008.
22. Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP and Haugen TH: Human papillomavirus and risk of oral cancer. Laryngoscope 108: 1098-1103, 1998.
23. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720, 2000.
24. D'Souza G, Kreimer AR, Viscidi R, et al: Case control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944-1956, 2007.
25. Pyeon D, Lambert PF and Ahlquist P: Production of infectious human papillomavirus independently of viral replication and epi-thelial cell differentiation. Proc Natl Acad Sci USA 102: 9311-9316, 2005.
26. Wiest T, Schwarz E, Enders C, Flechtenmacher C and Bosch FX: Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21: 1510-1517, 2002.
27. Califano J, van der Reit P, Westra W, et al: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492, 1996.
28. Goodwin EC and DiMaio D: Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 97: 12513-12518, 2000.
29. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR and Schiller JT: HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8: 3905-3910, 1989.
30. Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD and Howley PM: Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)- dependent pathways. EMBO J 19: 5762-5771, 2000.
31. Butz K, Geisen C, Ullmann A, Spitkovsky D and Hoppe-Seyler F: Cellular responses of HPV-positive cancer cells to genotoxic anti- cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 68: 506-513, 1996.
32. Bristow RG, Benchimol S and Hill RP: The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 40: 197-223, 1996.
33. Lindquist D, Romanitan M, Hammarstedt L, et al: Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 1: 350-355, 2007.
34. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, et al: Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19: 4611-4620, 2000.
35. Toussaint-Smith E, Donner DB and Roman A: Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 23: 2988-2995, 2004.
36. Tang X, Zhang Q, Nishitani J, et al: Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 13: 2568-2576, 2007.
37. Dahm-Daphi J: p53: biology and role for cellular radiosensitivity. Strahlenther Onkol 176: 278-285, 2000.
38. Lindel K, Beer KT, Laissue J, Greiner RH and Aebersold DM: Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92: 805-813, 2001.
39. De Wever O and Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 429-447, 2003.
40. Tlsty TD and Hein PW: Know their neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11: 54-59, 2001.
41. Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337, 2004.
42. Bhowmick NA, Chytil A, Plieth D, et al: TGFbeta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851, 2004.
43. Micke P and Ostman A: Exploring the tumor environment: cancer associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9: 1217-1233, 2005.
44. Joyce JA: Therapeutic targeting of the tumor microenvironment. Cancer Cell 7: 513-520, 2005.
45. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
46. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127-137, 1995.
47. Zhang HT, Craft P, Scott PA, et al: Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87: 213-219, 1995.
48. Eisma RJ, Spiro JD and Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174: 513-517, 1997.
49. Mineta H, Miura K and Ogino T: Prognostic value of vascular endothelial growth factor in head and neck squamous cell carcinomas. Br J Cancer 83: 775-781, 2000.
50. Salven P, Heikkilä P and Anttonen A: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 10: 1128-1133, 1997.
51. Riedel F, Götte K and Schwalb J: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257: 332-336, 2000.
52. Riedel F, Götte K and Schwalb J: Expression of vascular endothelial growth factor correlates with angiogenesis and p53 mutations in head and neck squamous cell carcinoma. Acta Otolaryngol 120: 105-111, 2000.
53. Le Buanec H, D'Anna R, Lachgar A, et al: HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed Pharmacother 53: 424-431, 1999.
54. Heldin CH and Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316, 1999.
55. Risau W, Drexler H, Mironov V, et al: Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7: 261-266, 1992.
56. Pietras K, Ostman A, Sjöquist M, et al: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934, 2001.
57. Forsberg K, Valyi-Nagy I and Heldin CH: Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90: 393-397, 1993.
58. Dong J, Grunstein J, Tejada M, et al: VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23: 2800-2810, 2004.
59. Shao ZM, Nguyen M and Barsky SH: Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19: 4337-4345, 2000.
60. Skobe M and Fusenig NE: Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 95: 1050-1055, 1998.
61. Bran B, Bran G and Hörmann K: The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenic therapy in head and neck cancer. Int J Oncol 34: 255-261, 2009.
62. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
63. Druker BJ and Lydon NB: Lessons learned from the development of an abl tyrosine-kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000.
64. O'Dwyer ME, Mauro MJ and Druker BJ: STI571 as a targeted therapy for CML. Cancer Invest 21: 429-438, 2003.
65. Roskoski R Jr: STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 309: 709-717, 2003.
66. Shore SK, Bogart SL and Reddy EP: Activation of murine c-Abl protooncogene: effect of a point mutation on oncogenic activation. Proc Natl Acad Sci USA 87: 6502-6506, 1990.
67. Croom KF and Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumors. Drugs 63: 513-522, 2003.
68. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
69. Beppu K, Jaboine J, Merchant MS, et al: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96: 46-55, 2004.
70. Vlahovic G, Ponce AM, Rabbani Z, et al: Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97: 735-740, 2007.
71. Wang-Rodriguez J, Lopez JP and Altuna X: STI-571 (Gleevec) Potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 116: 1409-1416, 2006.
72. Schultz JD, Rotunno S, Sauter A, et al: Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Ra/ß expression in squamous cell carcinoma of the head and neck in vitro. Int J Oncol 38: 1001-1012, 2011.
73. Matei D, Kelich S, Cao L, et al: PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 6: 1951-1959, 2007.